title: Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects.
abstract: BACKGROUND
  Prolonged treatment with omeprazole 20 or 40 mg/day is sometimes required, especially for severe oesophagitis. However, information about long-term effects on intragastric acidity and plasma gastrin response with such drug regimens is scarce.
  
  
  METHODS
  Sixteen healthy subjects (11 men, 5 women, mean age 29 years) randomly received either 20 or 40 mg of omeprazole once daily (at 08.00 h) for 3 months. Gastric pH was recorded every 6 s for 24 h from noon to noon under standardized conditions, and blood samples were collected hourly in order to determine the 24-h plasma gastrin response on day 0 (pre-entry), day 7, day 28 and day 90.
  
  
  RESULTS
  From day 0 to day 7, 24-h median pH increased from 1.7 to 4.6 and mean percentage of time at pH < 4 decreased from 89% to 35% with omeprazole 20 mg. Respective values with omeprazole 40 mg were 1.9 to 4.3, and 89% to 34%. Inhibition of gastric acidity remained unchanged during the 3 months of treatment. Despite similar effects on the basis of 24-h analysis, the decrease in daytime acidity was slightly higher with omeprazole 40 mg than with omeprazole 20 mg. Twenty-four-hour integrated plasma gastrin significantly increased with both drug regimens between day 0 and day 7 (P < 0.01), and between day 7 and day 28 (P < 0.01) with omeprazole 40 mg; there was no significant increase between day 28 and day 90 with either of the drug regimens.
  
  
  CONCLUSIONS
  Omeprazole 20 and 40 mg/day provides long-term stable acid suppression with a progressive increase in gastrin response, stabilizing after 2 months of treatment.
authors.affiliation: Départament de gastroentérologie des hôpitaux: Henri Mondor (Créteil), France.
authors.forename: J C
authors.initials: JC
authors.lastname: Delchier
authors.forename: R
authors.initials: R
authors.lastname: Benamouzig
authors.forename: L
authors.initials: L
authors.lastname: Stanescu
authors.forename: A
authors.initials: A
authors.lastname: Ropert
authors.forename: T
authors.initials: T
authors.lastname: Vallot
authors.forename: V
authors.initials: V
authors.lastname: Wirquin
authors.forename: F
authors.initials: F
authors.lastname: Roudot
authors.forename: D
authors.initials: D
authors.lastname: Lamarque
authors.forename: B
authors.initials: B
authors.lastname: Hamelin
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005755:Gastrins / Q000097:blood*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000494:pharmacology*; D054328:Proton Pump Inhibitors
chemical_list: D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D005755:Gastrins; D054328:Proton Pump Inhibitors; D009853:Omeprazole